Prescription drug · NDA AUTHORIZED GENERIC
Carbidopa (carbidopa tablets) NDC 68682-200
Carbidopa 25 mg/1 · Tablet · Oral · Oceanside Pharmaceuticals
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68682-200-25 | 68682020025 | 100 TABLET in 1 BOTTLE (68682-200-25)Marketed from Apr 4, 2014 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Carbidopa
- Generic name (nonproprietary)
- carbidopa tablets
- Active ingredients
- Carbidopa — 25 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Oceanside Pharmaceuticals
- Product type
- Prescription drug
- Marketing category
- NDA authorized genericApplication NDA 017830
- Marketing start
- Listing expires
- Identifiers
- Product ID 68682-200_ccf10efe-4fda-40a4-8f20-1ccefb151a15SPL ID ccf10efe-4fda-40a4-8f20-1ccefb151a15SPL set ID d5204e5e-10ef-4758-8fc6-cb710048c687RxCUI 260260UNII MNX7R8C5VO
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N468682020025followed by a unit qualifier and the quantityPackage 68682-0200-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication.…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 017830
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Lodosyncarbidopa | Carbidopa 25 mg/1 | TabletOral | Bausch Health US, LLC | 25010-711 |